Shree Pacetronix

Shree Pacetronix Net Debt / EBITDA

The Net Debt to EBITDA of Shree Pacetronix (527005.BO) as of Oct 23, 2026 is 1.69. In the previous year, Net Debt to EBITDA was 0.60 — a change of 184.03% (higher).

Net Debt / EBITDA

1.69

YoY

184.03%

Last updated:

Net Debt to EBITDA of Shree Pacetronix is 2025 1.69 . Net Debt to EBITDA of Shree Pacetronix was 2024 0.60 . It decreases by 184.03% higher compared to the previous year.

The Shree Pacetronix Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2016
6.72 INR
Jan 1, 2017
-42.83 INR
Jan 1, 2020
2.83 INR
Jan 1, 2021
3.11 INR
Jan 1, 2022
0.89 INR
Jan 1, 2023
0.24 INR
Jan 1, 2024
0.60 INR
Jan 1, 2025
1.69 INR
The Shree Pacetronix Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
1.69+184.03%
0.60+149.36%
0.24-73.18%
0.89-71.38%
3.11+9.96%
2.83-106.61%
-42.83-737.19%
6.72-39.70%
11.15+317.94%
2.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shree Pacetronix Stock analysis

What does Shree Pacetronix do? Shree Pacetronix Ltd. generates revenue through the sale of implantable cardiac pacemakers and related medical devices. The company's product portfolio includes multi-programmable pacemakers such as Ventralite 940 +/ Tiranga, Pinnacle 8820, and Tiranga 302, as well as rate responsive pacemakers like Charak DDDR and Pinnacle-R SSIR + Model 297. Bivent pacemakers such as Trinity R and external pacemakers including Indus I SSB and Zeus-1 are also sold. Additional products consist of pacing system analyzers, physician corners, and pacing leads like temporary leads, Screw-in lead P12 Model 3844 VB/ 3744VB, IS1 Bipolar Lead 3851 VB, and Atrial J Bipolar Lead 3851 VB. The company serves the Life Saving Devices segment with a focus on India and the Rest of the World, targeting healthcare providers and medical institutions requiring cardiac pacemaker solutions. Shree Pacetronix Ltd. operates under the Life Saving Devices segment, offering specialized medical equipment for cardiac care. Its subsidiary Shree Coratomic Limited supports the company's operations. The primary buyers are healthcare facilities and medical institutions in India and international markets, purchasing pacemakers and associated devices for patient treatment. Products are distributed through medical supply channels to hospitals and clinics specializing in cardiology. The firm's revenue streams are derived from the direct sale of its branded medical devices. Key products include the Ventralite 940 +/ Tiranga, Pinnacle 8820, Tiranga 302, Charak DDDR, Pinnacle-R SSIR + Model 297, Trinity R, Indus I SSB, Zeus-1, Smart-E programmer, and various pacing leads. These products are sold to healthcare providers globally, with significant market presence in India and the Rest of the World. The company's business model centers on providing essential cardiac care equipment through its comprehensive product range. Shree Pacetronix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shree Pacetronix stock

Net Debt to EBITDA of Shree Pacetronix is 1.69 in 2025.

Net Debt to EBITDA of Shree Pacetronix changed from 0.60 to 1.69, representing a 184.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Shree Pacetronix since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Shree Pacetronix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Shree Pacetronix

All Key Metrics — Shree Pacetronix